Deep Track, an investment firm, led a $150m Series E round in Carmot Therapeutics, a clinical-stage biotechnology company, with participation from 5AM Ventures, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, Millennium Management, TCGX, Venrock Healthcare Capital Partners and existing investors RA Capital Management, The Column Group and Willett Advisors. “We are thrilled to have such a reputable group of life science investors who value and recognize the progress we’ve made to date and share our vision of treating obesity and diabetes with novel incretin modulators. With three clinical-stage candidates currently in development, this financing enables us to continue to advance clinical trials that will yield key data readouts this year and through 2024," Heather Turner, Carmot CEO.